Compare JRSH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JRSH | SCYX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.5M | 41.0M |
| IPO Year | 2017 | 2014 |
| Metric | JRSH | SCYX |
|---|---|---|
| Price | $3.43 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $4.00 | $3.00 |
| AVG Volume (30 Days) | 83.1K | ★ 607.5K |
| Earning Date | 02-09-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | 56.25 | ★ 61.36 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $145,812,006.00 | $257,000.00 |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $10.06 | $608.78 |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | ★ 24.43 | N/A |
| 52 Week Low | $2.82 | $0.57 |
| 52 Week High | $3.60 | $1.29 |
| Indicator | JRSH | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 79.96 | 56.26 |
| Support Level | $3.20 | $0.72 |
| Resistance Level | $3.52 | $1.29 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 93.14 | 54.00 |
Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.